Evaluating the effectiveness of the National Health Insurance Fund in providing financial protection to households with hypertension and diabetes patients in Kenya.
Financial risk protection
Health expenditure
Health insurance
Kenya
Non-communicable diseases
Journal
International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
28
03
2023
accepted:
22
05
2023
medline:
5
6
2023
pubmed:
2
6
2023
entrez:
1
6
2023
Statut:
epublish
Résumé
Non-communicable diseases (NCDs) can impose a substantial financial burden to households in the absence of an effective financial risk protection mechanism. The national health insurance fund (NHIF) has included NCD services in its national scheme. We evaluated the effectiveness of NHIF in providing financial risk protection to households with persons living with hypertension and/or diabetes in Kenya. We carried out a prospective cohort study, following 888 households with at least one individual living with hypertension and/or diabetes for 12 months. The exposure arm comprised households that are enrolled in the NHIF national scheme, while the control arm comprised households that were not enrolled in the NHIF. Study participants were drawn from two counties in Kenya. We used the incidence of catastrophic health expenditure (CHE) as the outcome of interest. We used coarsened exact matching and a conditional logistic regression model to analyse the odds of CHE among households enrolled in the NHIF compared with unenrolled households. Socioeconomic inequality in CHE was examined using concentration curves and indices. We found strong evidence that NHIF-enrolled households spent a lower share (12.4%) of their household budget on healthcare compared with unenrolled households (23.2%) (p = 0.004). While households that were enrolled in NHIF were less likely to incur CHE, we did not find strong evidence that they are better protected from CHE compared with households without NHIF (OR = 0.67; p = 0.47). The concentration index (CI) for CHE showed a pro-poor distribution (CI: -0.190, p < 0.001). Almost half (46.9%) of households reported active NHIF enrolment at baseline but this reduced to 10.9% after one year, indicating an NHIF attrition rate of 76.7%. The depth of NHIF cover (i.e., the share of out-of-pocket healthcare costs paid by NHIF) among households with active NHIF was 29.6%. We did not find strong evidence that the NHIF national scheme is effective in providing financial risk protection to households with individuals living with hypertension and/diabetes in Kenya. This could partly be explained by the low depth of cover of the NHIF national scheme, and the high attrition rate. To enhance NHIF effectiveness, there is a need to revise the NHIF benefit package to include essential hypertension and/diabetes services, review existing provider payment mechanisms to explicitly reimburse these services, and extend the existing insurance subsidy programme to include individuals in the informal labour market.
Sections du résumé
BACKGROUND
Non-communicable diseases (NCDs) can impose a substantial financial burden to households in the absence of an effective financial risk protection mechanism. The national health insurance fund (NHIF) has included NCD services in its national scheme. We evaluated the effectiveness of NHIF in providing financial risk protection to households with persons living with hypertension and/or diabetes in Kenya.
METHODS
We carried out a prospective cohort study, following 888 households with at least one individual living with hypertension and/or diabetes for 12 months. The exposure arm comprised households that are enrolled in the NHIF national scheme, while the control arm comprised households that were not enrolled in the NHIF. Study participants were drawn from two counties in Kenya. We used the incidence of catastrophic health expenditure (CHE) as the outcome of interest. We used coarsened exact matching and a conditional logistic regression model to analyse the odds of CHE among households enrolled in the NHIF compared with unenrolled households. Socioeconomic inequality in CHE was examined using concentration curves and indices.
RESULTS
We found strong evidence that NHIF-enrolled households spent a lower share (12.4%) of their household budget on healthcare compared with unenrolled households (23.2%) (p = 0.004). While households that were enrolled in NHIF were less likely to incur CHE, we did not find strong evidence that they are better protected from CHE compared with households without NHIF (OR = 0.67; p = 0.47). The concentration index (CI) for CHE showed a pro-poor distribution (CI: -0.190, p < 0.001). Almost half (46.9%) of households reported active NHIF enrolment at baseline but this reduced to 10.9% after one year, indicating an NHIF attrition rate of 76.7%. The depth of NHIF cover (i.e., the share of out-of-pocket healthcare costs paid by NHIF) among households with active NHIF was 29.6%.
CONCLUSION
We did not find strong evidence that the NHIF national scheme is effective in providing financial risk protection to households with individuals living with hypertension and/diabetes in Kenya. This could partly be explained by the low depth of cover of the NHIF national scheme, and the high attrition rate. To enhance NHIF effectiveness, there is a need to revise the NHIF benefit package to include essential hypertension and/diabetes services, review existing provider payment mechanisms to explicitly reimburse these services, and extend the existing insurance subsidy programme to include individuals in the informal labour market.
Identifiants
pubmed: 37264458
doi: 10.1186/s12939-023-01923-5
pii: 10.1186/s12939-023-01923-5
pmc: PMC10234077
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214622
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 092654
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T023538/1
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Int J Health Plann Manage. 2019 Apr;34(2):e1166-e1178
pubmed: 30762904
J Health Econ. 2008 Jul;27(4):990-1005
pubmed: 18342963
BMC Health Serv Res. 2012 Mar 19;12:66
pubmed: 22424445
Int J Pharm Pract. 2016 Oct;24(5):358-66
pubmed: 26913925
Int J Equity Health. 2017 Feb 6;16(1):31
pubmed: 28166779
Int J Equity Health. 2020 Feb 3;19(1):19
pubmed: 32013955
Lancet Glob Health. 2018 Mar;6(3):e292-e301
pubmed: 29433667
Health Res Policy Syst. 2013 Aug 16;11:31
pubmed: 23947294
PLoS Med. 2014 Sep 22;11(9):e1001701
pubmed: 25244520
Health Policy Plan. 2014 Oct;29(7):912-20
pubmed: 24107660
BMJ Open. 2022 Mar 16;12(3):e056261
pubmed: 35296482
BMC Public Health. 2018 Nov 7;18(Suppl 3):1219
pubmed: 30400858
Health Syst Reform. 2018;4(4):346-361
pubmed: 30398396
Health Policy Plan. 2020 Aug 1;35(7):842-854
pubmed: 32537642
BMJ Glob Health. 2020 Feb 11;5(2):e002040
pubmed: 32133191
BMJ Glob Health. 2021 Apr;6(4):
pubmed: 33903176
PLoS One. 2016 Jan 21;11(1):e0146508
pubmed: 26795620
Int J Equity Health. 2013 May 30;12:38
pubmed: 23718769
Health Econ. 2004 Jul;13(7):609-28
pubmed: 15259042
BMJ Open. 2023 Jul 4;13(7):e069330
pubmed: 37407061
BMC Health Serv Res. 2015 Jan 22;15:26
pubmed: 25608983
Bull World Health Organ. 2008 Nov;86(11):857-63
pubmed: 19030691
Bull World Health Organ. 2010 Jun;88(6):402
pubmed: 20539847
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Int J Health Plann Manage. 2020 Jan;35(1):290-308
pubmed: 31621953
Iran J Public Health. 2014 Jun;43(6):736-48
pubmed: 26110144
BMC Public Health. 2018 Nov 7;18(Suppl 3):1215
pubmed: 30400865
Wellcome Open Res. 2017 Sep 28;2:94
pubmed: 29387800
BMJ Glob Health. 2018 Jun 27;3(3):e000904
pubmed: 29989036
Health Policy Plan. 2013 Aug;28(5):467-79
pubmed: 22987824
Front Health Serv. 2022 Apr 05;2:786098
pubmed: 36925851
BMJ Open. 2020 May 15;10(5):e035132
pubmed: 32414824
J Health Econ. 2009 Mar;28(2):504-15
pubmed: 18367273
Health Syst Reform. 2020;6(1):1-15
pubmed: 31592715
Lancet. 2003 Jul 12;362(9378):111-7
pubmed: 12867110
BMC Health Serv Res. 2016 Sep 08;16:481
pubmed: 27608976
Int J Equity Health. 2009 Dec 09;8:42
pubmed: 20003188
PLoS One. 2018 Jan 5;13(1):e0190113
pubmed: 29304049
Lancet. 2018 May 19;391(10134):2047-2058
pubmed: 29627161